CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that the Company will participate in four investor conferences in February:
•2016 Canaccord Genuity Rare Disease, BioPharma One-On-One Day, Tuesday, February 2 at the Omni Berkshire Place in New York.
